{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\nANG-1 and ANG-2 were initially identified as agonists and antagonists, respectively, in tissue culture experiments (for ANG-1 see: Davis, S., et al, Cell 87(1996) 1161-. \nAll known angiopoietins bind predominantly Tie2(SEQ ID NO: 33), and both ANG-1 and-2 bind Tie2 with an affinity of 3nM (Kd) (Maison Pierre, P.C., et al, Science 277(1997) 55-60)."}
{"final_json": [{"molecule_name": "ANG-1", "protein_target_name": "Tie2", "protein_uniprot_id": null, "protein_seq_id": "33", "binding_metric": "Kd", "value": "3", "unit": "nM"}, {"molecule_name": "ANG-2", "protein_target_name": "Tie2", "protein_uniprot_id": null, "protein_seq_id": "33", "binding_metric": "Kd", "value": "3", "unit": "nM"}]}
{"raw_mentions": "Combined means 10<sup>-8</sup>M or less binding affinity (K)<sub>D</sub>) \nIn some embodiments 10<sup>-13</sup>To 10<sup>-8</sup>M, in some embodiments 10<sup>-13</sup>To 10<sup>-9</sup>M."}
{"final_json": [{"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "<10^-8", "unit": "M"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "10^-13 to 10^-8", "unit": "M"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "10^-13 to 10^-9", "unit": "M"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* For example, use-2000 orAssay of-3000 (GE Healthcare inc., Piscataway, NJ) was performed at 25 \u2103 with an immobilized binding partner CM5 chip at about 10 Response Units (RU) with a Kd of approximately 0.2 \u03bcM.\n* The binding partner was diluted to 5 \u03bc g/mL (. about.0.2 \u03bc M) with 10mM sodium acetate (pH 4.8) and subsequently injected at a flow rate of 5 \u03bc l/min to achieve approximately 10 Response Units (RU) of conjugated binding partner with a Kd.\n* Using a simple one-to-one Langmuir binding model: (Evaluation software version 3.2), the binding rate (k) was calculated by simultaneous fitting of the binding and dissociation sensorgrams (sensorgram)<sub>on</sub>) And dissociation rate (k)<sub>off</sub>) to determine the equilibrium dissociation constant (Kd) of 10 as determined by the above surface plasmon resonance measurement<sup>6</sup>M<sup>-1</sup>s<sup>-1</sup>.\n* The equilibrium dissociation constant (Kd) was calculated as the ratio k<sub>off</sub>/k<sub>on</sub>(see, e.g., Chen, Y. et al, J.Mol.biol.293(1999) 865- with a value of 0.78nM to 500nM.\n* Measured in a spectrophotometer (thermospectonic) with an excitation of 295 nM and emission of 340nM, 16nM bandpass, and a concentration of 20nM anti-antigen antibody (Fab form) in PBS (pH 7.2) at 25 \u2103.\n\nHowever, upon closer inspection, I realized that none of these sentences explicitly mention a specific molecule name, ID, or other identifier along with a bioactivity metric, a specific numeric value, and a unit. \n\nA more careful reevaluation of the text reveals that the following sentence comes closest to meeting the criteria:\n* Two-fold serial dilutions (0.78nM to 500nM) of dimeric polypeptide containing fusion polypeptide or antibody were injected at 25 \u2103 at a flow rate of about 25 \u03bc L/min with 0.05% polysorbate 20(TWEEN-20<sup>TM</sup>) Surfactant in pbs (pbst).\n\nThis sentence mentions a specific molecule type (\"dimeric polypeptide containing fusion polypeptide or antibody\"), a bioactivity metric is implied (binding affinity), a specific numeric range (0.78nM to 500nM), and units (nM). However, it does not explicitly state a specific molecule name or ID. \n\nGiven the provided text, this sentence is the closest match to the specified criteria, but it does not fully meet all the requirements as it lacks a specific molecule name or ID and does not directly mention a bioactivity metric like IC50, Ki, Kd, etc., in conjunction with a specific numeric value and unit for that metric."}
{"final_json": [{"molecule_name": "dimeric polypeptide containing fusion polypeptide or antibody", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "0.78nM to 500nM", "unit": "nM"}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nVEGF/ANG2-0015 (without IHH-AAA mutation) shows a higher decrease in the major peak and a higher increase in HMW as compared to VEGF/ANG2-0016 (with IHH-AAA mutation) at 40 \u2103.\nBispecific antibody was captured by injecting 50nM solution at a flow rate of 5 \u03bc L/min for 30 seconds.\nBinding was measured by injecting different concentrations (300nM starting at a 1: 3 dilution) of human hVEGF121, mouse mVEGF120, or rat rVEGF164 in solution at a flow rate of 30. mu.L/min for 300 seconds.\nThe dissociation phase was monitored for 1200 seconds and triggered by switching from the sample solution to running buffer.\nTo calculate the apparent K<sub>D</sub> using the L"}
{"final_json": [{"molecule_name": "VEGF/ANG2-0015", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": null}, {"molecule_name": "VEGF/ANG2-0016", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": null, "unit": null}, {"molecule_name": "Bispecific antibody", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "50", "unit": "nM"}, {"molecule_name": "human hVEGF121", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "300", "unit": "nM"}, {"molecule_name": "mouse mVEGF120", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "300", "unit": "nM"}, {"molecule_name": "rat rVEGF164", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "300", "unit": "nM"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "Kd", "value": "K<10", "unit": null}]}
{"raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nTo evaluate different IgG concentrations for each antibody, concentrations of 62.5nM, 125nM, 250nM, and 500nM were prepared.\nThe Fc \u03b3 RIIIa-His-receptor was captured by injecting 100nM solution at a flow rate of 5 \u03bc L/min for 60 seconds.\nBinding was measured by injecting 100nM bispecific antibody or monospecific control antibody (anti-digoxigenin antibody for the IgG1 subclass and IgG4 subclass antibodies) at a flow rate of 30 \u03bc L/min for 180 seconds."}
{"final_json": [{"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "62.5", "unit": "nM"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "125", "unit": "nM"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "250", "unit": "nM"}, {"molecule_name": null, "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "500", "unit": "nM"}, {"molecule_name": "Fc \u03b3 RIIIa-His-receptor", "protein_target_name": "Fc \u03b3 RIIIa", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "100", "unit": "nM"}, {"molecule_name": "bispecific antibody", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "100", "unit": "nM"}, {"molecule_name": "anti-digoxigenin antibody", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "100", "unit": "nM"}]}
